Largactil (Chlorpromazine Hydrochloride)

Chlorpromazine blocks dopamine D2 receptors and also antagonises histamine, muscarinic, and alpha‑adrenergic receptors. This reduces dopaminergic activity in brain pathways responsible for psychosis while providing sedative, anti‑emetic, and vasodilatory effects that contribute to symptom control.

The dosage of Largactil is individualized by the prescribing clinician based on the patient’s condition, severity, and response. Dosing regimens are determined by the treating physician and may be adjusted over time.

Safety data for chlorpromazine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use only if the potential benefit justifies the potential risk, and discuss with a healthcare professional before starting therapy.

To request Largactil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Largactil belongs to the phenothiazine class, offering broad receptor antagonism that provides strong sedative and anti‑emetic effects. Compared with newer atypical antipsychotics, it may have a higher incidence of movement‑related side effects but can be useful when rapid calming is needed or when cost considerations are paramount.

Largactil should be stored at temperatures below 25 °C, in its original packaging, protected from light and moisture. Maintaining these conditions helps preserve the stability and potency of the injectable solution.

Largactil is supplied as an injectable solution for intramuscular or intravenous administration. The route, injection site, and rate of infusion are determined by the prescribing clinician and should be performed by qualified healthcare personnel.

Serious risks include neuroleptic malignant syndrome, tardive dyskinesia, severe cardiac arrhythmias (including QT prolongation), and agranulocytosis. Patients should be monitored closely for signs such as high fever, muscle rigidity, irregular heartbeats, or unexplained infections.

Largactil is contraindicated in patients with known hypersensitivity to chlorpromazine or any phenothiazine component, those with severe cardiovascular disease, uncontrolled narrow‑angle glaucoma, and individuals who are currently taking MAO inhibitors. Clinical judgment is required for other special populations.